Dermatology

The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News

Four weeks of therapy with ruxolitinib led to a significant benefit on numerous assessments. | Image Credit: Peakstock - stock.adobe.com
Managing Both Physical, Mental Health Key for QOL in Vitiligo

August 23rd 2025

Patients reported quality-of-life benefits from treatment for nonsegmental vitiligo, even when clinical improvement started slowly.

AJMC Q&A with Elizabeth Garcia Creighton | Background image credit: ipopba - stock.adobe.com
Navigating Challenges in Pediatric Dermatology Access, Addressing Disparities: Elizabeth Garcia Creighton

August 17th 2025

Hidradenitis suppurativa. | Image Credit: Kristina Blokhin - stock.adobe.com
GLP-1s Show Promise for Patients With Hidradenitis Suppurativa and Obesity

August 15th 2025

AJMC Q&A with Elizabeth Garcia Creighton | Background image credit: ipopba - stock.adobe.com
Challenges in Getting Access to an Initial Pediatric Dermatology Appointment: Elizabeth Garcia Creighton

August 10th 2025

Hidradenitis suppurativa. | Image Credit: JPC-PROD - stock.adobe.com
Comparative Efficacy of Hidradenitis Suppurativa Drugs Examined in Absence of Head-to-Head Trials

August 5th 2025

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives
Continuing Medical Education
View All
August 29th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 29th 2025

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professionals

August 19, 2025 | 1:00 PM & 8:00 PM ET
August 29th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Emergency department.
November 1st 2022

Hidradenitis Suppurativa ED Readmission Linked to Opioid Prescribing, Medicaid Insurance

Matthew Gavidia
Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.
Athena Gierbolini, president of Hope for HS.
October 26th 2022

Advocate Discusses Misconceptions, Culturally Sensitive Care for Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), spoke on common stigmas regarding HS and how clinicians can improve consultation through a culturally sensitive approach.
Man scratching rash
October 20th 2022

Review Explores Potential Treatments for Prurigo Nodularis

Julia Bonavitacola
A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor.
doctor in hospital.
October 18th 2022

Exploring Strategies for Timely Diagnosis, Comprehensive Care in Hidradenitis Suppurativa

Matthew Gavidia
Researchers reviewed clinical features of hidradenitis suppurativa and provided strategies to promote earlier identification, differentiation from common mimickers, and timely referrals for multidisciplinary management.
Athena Gierbolini, president of Hope for HS.
October 13th 2022

Advocate Speaks on Diet, Holistic Care in Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), discusses current knowledge on the impact of diet and other holistic care strategies in the management of HS.
Surgery.
October 10th 2022

Assessing Surgical Complications in Management of Hidradenitis Suppurativa

Matthew Gavidia
Approximately 1 in 10 patients with hidradenitis suppurativa (HS) experienced complications related to surgery for HS management, in which extensive resection, using skin flaps or skin grafts as a closure method, was associated with a higher incidence of complications.
Athena Gierbolini.
October 7th 2022

Advocate Addresses Unmet Needs in the Management of Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed several pressing issues that warrant consideration to improve the care management of HS.
Black woman.
October 5th 2022

Worse Outcomes Seen Among Black Patients With Hidradenitis Suppurativa

Matthew Gavidia
Black patients with hidradenitis suppurativa were more likely to experience greater disease severity, emergency department visits, hospitalizations, and surgeries than non-Hispanic White patients.
Doctor and patient.
September 24th 2022

Evaluating Factors Associated With Treatment Satisfaction in Hidradenitis Suppurativa

Matthew Gavidia
Tobacco smoking, depression, and increasing number of comorbidities were associated with reduced treatment satisfaction among patients with hidradenitis suppurativa.
Athena Gierbolini.
September 23rd 2022

Advocate Discusses Surgical, Therapeutic Management of Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), spoke on the surgical and therapeutic interventions she’s had for the management of HS.
Athena Gierbolini.
September 16th 2022

Advocate Details Challenges Faced in Path to Diagnosis for Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed the misconceptions she faced from clinicians regarding her clinical symptoms of HS prior to diagnosis.
Doctor examining patient.
September 14th 2022

Secukinumab Shows Rapid, Sustained Improvement of Hidradenitis Suppurativa

Matthew Gavidia
SUNSHINE and SUNRISE trial data will be submitted to the FDA as part of Novartis’ Biologics License Application (BLA) for secukinumab in hidradenitis suppurativa.
Athena Gierbolini.
September 9th 2022

Advocate Discusses Physical, Psychological Impact of Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), speaks on the quality of life burden she has experienced during her HS disease journey.
Older man.
September 3rd 2022

Pain and Late Onset of Hidradenitis Suppurativa May Affect Employment, Educational Level

Matthew Gavidia
Inactive occupational status and low educational level were associated with pain, late disease onset, and greater number of affected areas in patients with hidradenitis suppurativa.
Brindley Brooks.
August 27th 2022

Advocate Highlights Misconceptions in the Management of Hidradenitis Suppurativa

Matthew Gavidia
Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected by hidradenitis suppurativa (HS), spoke on misconceptions she’s encountered on her HS disease journey and the importance for physicians to be conscientious of their advice to patients.
Doctor and patients.
August 24th 2022

Clinical Features, Management of Acne Fulminans Explored in New Case Report

Matthew Gavidia
A case report of a patient with acne fulminans, a rare form of acne vulgaris, discussed the clinical manifestations of the disease, physical examination findings, and management strategies.
Brindley Brooks, who founded HS Connect.
August 20th 2022

Advocate Speaks on Critical Research Needs in Hidradenitis Suppurativa

Lindsey Mulrooney Matthew Gavidia
Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on key areas of HS comprehension and management that warrant further investigation in clinical research.
Picture of psoriasis
August 17th 2022

Real-world Data Confirm Early Efficacy of Anti-IL-17A Inhibitors for Psoriasis

Jaime Rosenberg
Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.
Brindley Brooks, who founded HS Connect.
August 13th 2022

Advocate Speaks on Prior Authorization, Insurance-Related Barriers for HS Treatment

Lindsey Mulrooney Matthew Gavidia
Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), discussed step edits and other barriers to treatment caused by insurance requirements in the management of HS.
Brindley Brooks, HS Connects.
August 5th 2022

Advocate Addresses Factors Physicians Should Consider in Managing Hidradenitis Suppurativa

Lindsey Mulrooney Matthew Gavidia
Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on the need for awareness among physicians and patients on the clinical features of HS in regard to both physical and psychosocial burdens.
Doctor and patient.
August 3rd 2022

Care Management Considerations for LGBTQIA Patients With Hidradenitis Suppurativa

Matthew Gavidia
A review explores critical factors for dermatologists to consider in managing the physical and behavioral care needs of LGBTQIA patients with hidradenitis suppurativa.
Brindley Brooks
July 30th 2022

Advocate Discusses Her Family's History With Hidradenitis Suppurativa

Lindsey Mulrooney
The journey to a diagnosis of hidradenitis suppurativa was different for her compared with the path faced by her children, said Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with the disease.
Heart.
July 25th 2022

Risk of Myocardial Infarction Greater Among Patients With Hidradenitis Suppurativa

Matthew Gavidia
An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.
cream.
July 19th 2022

FDA Approves Ruxolitinib Cream as First Repigmentation Therapy for Vitiligo

Matthew Gavidia
Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment for repigmentation in patients with vitiligo.
Frontal Fibrosing Alopecia Negatively Impacts HRQOL, Say Patients
July 18th 2022

Frontal Fibrosing Alopecia Negatively Impacts HRQOL, Say Patients

Jaime Rosenberg
Over half of the patients (53%) included in the study indicated that frontal fibrosing alopecia had a negative impact on their health-related quality of life (HRQOL).
Jonathan Kentley, MBBS, MSc,
July 16th 2022

Dr Jonathan Kentley Discusses Training Algorithms to Detect Melanoma

Hayden E. Klein
Many algorithms claiming to identify melanoma better than dermatologists are trained on retrospective datasets, which is not reflective of real-world clinical practice, said Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center.
Dermatologist inspecting patient.
July 12th 2022

Hidradenitis Suppurativa Linked With Wound Complications Following Total Joint Arthoplasty

Matthew Gavidia
The risk of wound-related issues was approximately 2-fold in adult patients with hidradenitis suppurativa (HS) undergoing total hip/knee arthroplasty vs those without HS.
David Rosmarin, MD
July 6th 2022

Dr David Rosmarin on How Vitiligo Impacts Quality of Life

Hayden E. Klein
Individuals tend to be more affected by vitiligo if it is visible on their face or hands, said David Rosmarin, MD, vice chair of research and education, Department of Dermatology, Tufts Medical Center.
acne on face
July 1st 2022

Only 2 Acne-Specific PROMs Receive ‘A’ Rating for Measuring Quality of Life

Lindsey Mulrooney
Of 10 patient-reported outcome measures studied, only 2 received an ‘A’ rating for sufficient content validity and internal structure.
Dr Jonathan Kentley: Physicians Are Working Alongside AI, Not Being Replaced by It
June 30th 2022

Dr Jonathan Kentley: Physicians Are Working Alongside AI, Not Being Replaced by It

Hayden E. Klein
Jonathan Kentley, MBBS, MSc, research fellow at Memorial Sloan Kettering Cancer Center, talks about how dermatologists are working with artificial intelligence (AI) while still making sure patient voices are heard.
<1
...
4567891011>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo